Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2009

View Archived Issues

Meta-analyses describe the effects of liraglutide in type 2 diabetes

WAY-364416 potentiates the activity of known antipsychotics, improves cognitive function

Improved endothelial function seen with insulin VIAject in type 2 diabetes

LBH-589, a promising candidate for the treatment of spinal muscular atrophy

Yuhan Research Institute discovers glucokinase activator with antidiabetes potential

RaQualia Pharma reports on novel TRPM8 antagonists as analgesic candidates

INK-055 shows promise in mouse model of collagen-induced arthritis

Champions Biotechnology signs licensing agreement with Ramot for TAR-1

FDA approves assay to aid in the diagnosis of rheumatoid arthritis

Astellas submits MAA to EMEA for telavancin for nosocomial pneumonia and cSSTI

Sanofi-aventis and Micromet sign license agreement for solid tumor BiTE antibody

Daiichi submits application to manufacture and market levofloxacin injection in Japan

Sangamo BioSciences receives CIRM award to develop ZFN-based therapy for AIDS

Cyclacel reports survival data from phase II sapacitabine trial in elderly AML patients

Ipsen's taspoglutide meets primary endpoint in Roche's first phase III trial in diabetes

Amgen reports results of third quarter of 2009

Cardiome and Astellas initiate enrollment in phase III trial of Kynapid for AF

Purinergic receptor antagonists discovered by Renovis for the treatment of pain

SYK and Janus kinase inhibitors claimed by Roche for autoimmune disorders

Wyeth discloses novel PI3K inhibitors for cancer treatment

Kowa describes new LXRbeta agonists

Paion's short-acting anesthetic/sedative CNS-7056 meets phase Ib trial endpoint

Forest Laboratories reports results from phase IIb cariprazine study in schizophrenia

AdvanDx receives FDA clearance for its 90-minute E. faecalis test

Rules-Based Medicine launches CardiovascularMAP

FDA clears D3 FastPoint L-DFA influenza A/influenza B virus identification kit